Percutaneous Coronary Intervention versus Optimal Medical Therapy on Quality of Life and Functional Capacity Assessment in Chronic Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials
Authors: Ibrahim Sammudeen , Allihien Saint-Martin , Addo Basilio , Osman Abdul-Fatawu , Amoateng Richard , Sulemana Haifz , Ozaeta Jan Camille L. , Opare-Addo Kwasi Asamoah , Dadzie Samuel , Arhinful Benedicta , Singireddy Shreyas , Kesiena Onoriode , Dodoo Sheriff N. , Bhavsar Vedang 
Published: July 2024

ABSTRACTBackgroundPrevious studies have primarily examined the impact of percutaneous coronary intervention (PCI) compared to optimal medical therapy (OMT) on hard outcomes such as all-cause mortality, cardiovascular death, nonfatal myocardial infarction, and the need for revascularization in patients with chronic coronary syndrome (CCS). However, these studies have not yielded significant findings thus far.ObjectiveThe goal of this meta-analysis was to assess the effect of PCI plus OMT on quality of life (QoL), functional capacity (FC), and angina-related health status compared to OMT alone in patients with CCS.MethodCochrane Central Registry of Controlled Trials, PubMed, Embase, andclininalTrials.govwere searched for studies published up to December 2023. The outcomes of interest were quality of life (QoL), freedom from angina (FFA), angina frequency (AF), and functional capacity (FC) measured with Seatle Angina Questionnaire (SAQ) or its equivalents such as EuroQol-5D (EQ-5D), 36-Item Short Form (SF-36) or RAND-36, and psychological well-being score if none is available. Additionally, the Duke Activity Status Index was also used to assess functional capacity when reported. Fixed-effect model was used for data analysis if I2statistics <50%; otherwise, the random-effect model was used. Sensitivity analysis was performed by using the leave-one-out meta-analysis which alternatively removes a trial from the study to assess its impact on the result as well as the interconversion between fixed-effects and random-effects models. A meta-regression analysis was also performed to evaluate the impact of covariates on QoL. Cochrane Risk of Bias Assessment Tool was used to assess the risk of bias.ResultsSeventeen randomized controlled trials that enrolled 13,588 patients satisfied our inclusion and exclusion criteria with an average age of 62.3±10 years. PCI plus OMT improved QoL with standardized mean difference (SMD) of 0.27 ([95% CI, 0.14-0.40]; P <0.001) and 0.21 ([95% CI, 0.12-0.30]; P <0.001) when compared to OMT alone at 6 months and 1 year respectively. PCI plus OMT was also associated with significant improvement in FFA (1.17 [95% CI, 1.11-1.24]; P < 0.001), AF (0.25 [95% CI, 0.20-0.30]; P <0.001), and FC (0.21 [95% CI, 0.12-0.31]; P <0.001) at 6 months and persisted at 3 years (QoL [0.18 [95% CI, 0.06-0.30]; P < 0.001], FFA [1.27 [95% CI, 1.11-1.45]; P < 0.001], AF [0.09 [95% CI, 0.02-0.16]; P = 0.009], FC [0.13 [95% CI, 0.02-0.23]; P = 0.02] respectively) . However, there appears to be a reduction in this effect with time. Meta-regression analysis using year of publication as covariate on QoL was performed. There was no statistically significant relationship between the year of publication and QoL at 1 year (P = 0.81).ConclusionIn this meta-analysis, PCI combined with OMT was associated with better quality of life, greater freedom from angina, reduction in angina frequency, and improved functional capacity compared to OMT alone. These benefits persisted when followed longitudinally for 3 years. However, longer-term outcome data of these trials is needed to determine whether these improvements in quality of life are sustained or attenuated over time.